181 related articles for article (PubMed ID: 19633067)
1. Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Deeken JF; Robey RW; Shukla S; Steadman K; Chakraborty AR; Poonkuzhali B; Schuetz EG; Holbeck S; Ambudkar SV; Bates SE
Mol Pharmacol; 2009 Nov; 76(5):946-56. PubMed ID: 19633067
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
3. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
4. The challenge of exploiting ABCG2 in the clinic.
Robey RW; Ierano C; Zhan Z; Bates SE
Curr Pharm Biotechnol; 2011 Apr; 12(4):595-608. PubMed ID: 21118093
[TBL] [Abstract][Full Text] [Related]
5. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
Holland ML; Lau DT; Allen JD; Arnold JC
Br J Pharmacol; 2007 Nov; 152(5):815-24. PubMed ID: 17906686
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
7. A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.
Antczak C; Wee B; Radu C; Bhinder B; Holland EC; Djaballah H
Assay Drug Dev Technol; 2014; 12(1):28-42. PubMed ID: 23992118
[TBL] [Abstract][Full Text] [Related]
8. New inhibitors of ABCG2 identified by high-throughput screening.
Henrich CJ; Robey RW; Bokesch HR; Bates SE; Shukla S; Ambudkar SV; Dean M; McMahon JB
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3271-8. PubMed ID: 18089721
[TBL] [Abstract][Full Text] [Related]
9. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Hardwick LJ; Velamakanni S; van Veen HW
Br J Pharmacol; 2007 May; 151(2):163-74. PubMed ID: 17375082
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
11. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
12. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
[TBL] [Abstract][Full Text] [Related]
13. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
14. ABCG2: structure, function and role in drug response.
Polgar O; Robey RW; Bates SE
Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
[TBL] [Abstract][Full Text] [Related]
15. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
16. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
17. ABCG2: a perspective.
Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
19. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Robey RW; Obrzut T; Shukla S; Polgar O; Macalou S; Bahr JC; Di Pietro A; Ambudkar SV; Bates SE
Cancer Chemother Pharmacol; 2009 Aug; 64(3):575-83. PubMed ID: 19132374
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
